The inaugural 2021 ACCP Trends in Drug Development Virtual Workshop was a great success! Check back soon for the 2022 ACCP Trends in Drug Development Workshop dates.
The Workshop is a Live, online event over two days that addresses cutting-edge topics in pre-clinical and clinical drug development relevant to clinical pharmacologists primarily working in industry. The diverse Faculty Speakers are experts in their respective research area and will provide a current perspective on research and development, including application to the drug development process and clinical pharmacology. The topics are specifically tailored to current developments including novel drug delivery techniques, safety of biologics, cell-based therapies for cancer and accelerated development of vaccines.
Meeting Dates: February 24 - 25, 2021
CE Credits: 7 CME or 7 CPE credits
Wednesday, February 24
1:00 – 2:00 PM | Keynote Presentation | Patient Adherence: Where the Rubber Meets the Road
Description: Contemporary drug development involves increasingly complex technology, and yet the results depend on a critical non-technical step that is often not measured in clinical trials-patient adherence. Adherence to medication use is seldom quantified in clinical studies, despite its overwhelming effects on study power, as well as efficacy and safety results. This session will explore the importance of adherence in clinical development, and explore reasons why adherence is still neglected in contemporary clinical development.
2:00 – 3:30 PM | Multifunctional
Dendrimer Nanotechnology for Drug Delivery
Description: Dendrimer nanotechnology is a new drug delivery system on the horizon. This presentation discusses the use of dendrimers for drug delivery and its application to deliver small molecules and biomolecules via various routes of administration. It will also touch upon the future of the technology.
3:30 – 4:00 PM | Break
4:00 – 5:30 PM | Safety of Biologics & Implication in Drug Development of Biologic Therapy
Description: Biologics are a diverse group of immunomodulatory agents that have revolutionized the treatment of inflammatory arthritis and related autoimmune and inflammatory conditions. These agents can target cytokines, specific immune cell populations and pathways of intercellular communication to block essential disease mechanisms. These agents are highly effective and ameliorate diseases such as rheumatoid arthritis, psoriasis, psoriatic arthritis and systemic lupus erythematosus (SLE) among other conditions. As a group, these conditions are associated with increased cardiovascular disease that may not be explained by conventional risk factors. An important question therefore is whether biologic therapy can affect cardiovascular risk. Given the targeting of key immunological pathways, there are concerns over safety involving increased infection. Fortunately, overall risk of infection seems comparable to other non-biologic therapies used for the same indications. Clinical trials have raised concerns over other side effects such as heart failure, major cardiovascular events and neuropsychiatric complications such as depression and suicidal ideation. Assessing the occurrence of these side effects can be difficult, relying on epidemiology and data from large registries. In some instances, animal models can provide useful data to assess the likelihood that a pathway or cytokine can cause the side effect in question.
Thursday, February 25
1:00 – 2:30 PM | The Game Changing Impact of Living Drugs: Development, Safety & Examples of Cell Based Cancer Therapy
Description: This session will describe some of the unique development considerations of cells as drugs and will explain the relationship between cell modifications and the potential for increased adverse events.
2:30 – 3:00 PM | Break
3:00 – 4:30 PM | Rapid COVID-19 Vaccine Development
Description: This session will describe the reasons we were able to respond quickly to the SARS-CoV-2 pandemic. These include access to new technologies to design antigens with greater precision and platform manufacturing of vaccine delivery vehicles for rapid production.